These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 26391050)

  • 1. Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.
    Hamlett ED; Boger HA; Ledreux A; Kelley CM; Mufson EJ; Falangola MF; Guilfoyle DN; Nixon RA; Patterson D; Duval N; Granholm AC
    Curr Alzheimer Res; 2016; 13(1):35-52. PubMed ID: 26391050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.
    Wegiel J; Flory M; Kuchna I; Nowicki K; Wegiel J; Ma SY; Zhong N; Bobrowicz TW; de Leon M; Lai F; Silverman WP; Wisniewski T
    Acta Neuropathol Commun; 2022 Jan; 10(1):2. PubMed ID: 34983655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.
    Lockrow J; Boger H; Gerhardt G; Aston-Jones G; Bachman D; Granholm AC
    J Alzheimers Dis; 2011; 23(3):471-89. PubMed ID: 21098982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD).
    Alldred MJ; Lee SH; Petkova E; Ginsberg SD
    Brain Struct Funct; 2015 Sep; 220(5):2983-96. PubMed ID: 25031177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related neurodegeneration and memory loss in down syndrome.
    Lockrow JP; Fortress AM; Granholm AC
    Curr Gerontol Geriatr Res; 2012; 2012():463909. PubMed ID: 22545043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging and intellectual disability: insights from mouse models of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Dev Disabil Res Rev; 2013; 18(1):43-50. PubMed ID: 23949828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.
    Kazim SF; Blanchard J; Bianchi R; Iqbal K
    Sci Rep; 2017 Apr; 7():45561. PubMed ID: 28368015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
    Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from mouse models to understand neurodegeneration in Down syndrome.
    Fillat C; Dierssen M; de Lagrán MM; Altafaj X
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):429-38. PubMed ID: 20522013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical aging in Down syndrome.
    Zigman WB
    Dev Disabil Res Rev; 2013; 18(1):51-67. PubMed ID: 23949829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designer receptors enhance memory in a mouse model of Down syndrome.
    Fortress AM; Hamlett ED; Vazey EM; Aston-Jones G; Cass WA; Boger HA; Granholm AC
    J Neurosci; 2015 Jan; 35(4):1343-53. PubMed ID: 25632113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.
    Lockrow J; Prakasam A; Huang P; Bimonte-Nelson H; Sambamurti K; Granholm AC
    Exp Neurol; 2009 Apr; 216(2):278-89. PubMed ID: 19135442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience-dependent reduction of soluble β-amyloid oligomers and rescue of cognitive abilities in middle-age Ts65Dn mice, a model of Down syndrome.
    Sansevero G; Begenisic T; Mainardi M; Sale A
    Exp Neurol; 2016 Sep; 283(Pt A):49-56. PubMed ID: 27288239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.
    Cenini G; Fiorini A; Sultana R; Perluigi M; Cai J; Klein JB; Head E; Butterfield DA
    Free Radic Biol Med; 2014 Nov; 76():89-95. PubMed ID: 25151119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Curr Opin Neurobiol; 2012 Oct; 22(5):880-6. PubMed ID: 22658745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
    Head E; Lott IT; Wilcock DM; Lemere CA
    Curr Alzheimer Res; 2016; 13(1):18-29. PubMed ID: 26651341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.
    Rueda N; Flórez J; Dierssen M; Martínez-Cué C
    Prog Brain Res; 2020; 251():245-268. PubMed ID: 32057309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.
    Tramutola A; Pupo G; Di Domenico F; Barone E; Arena A; Lanzillotta C; Brokeaart D; Blarzino C; Head E; Butterfield DA; Perluigi M
    J Alzheimers Dis; 2016; 52(1):359-371. PubMed ID: 26967221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.